Last reviewed · How we verify
Pimasertib twice daily
At a glance
| Generic name | Pimasertib twice daily |
|---|---|
| Sponsor | EMD Serono |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer (PHASE2)
- Trial of MSC1936369B in Subjects With Solid Tumors (PHASE1)
- Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma (PHASE2)
- A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy (PHASE1)
- Trial of Pimasertib in Hematological Malignancies (PHASE2)
- Oral Bioavailability and Mass Balance Trial With Pimasertib (PHASE1)
- Relative Bioavailability of Pimasertib in Cancer Patients (PHASE1)
- Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pimasertib twice daily CI brief — competitive landscape report
- Pimasertib twice daily updates RSS · CI watch RSS
- EMD Serono portfolio CI